Dexamethasone Dose Reductions in NDMM: No Impact on Survival Outcomes
Dexamethasone is a key component of induction therapy for newly diagnosed multiple myeloma (NDMM), but its use is often associated with toxicities such as hyperglycemia and insomnia....
MS, MMSc, PA-C
Associate Chief of Education, Winship Cancer Institute of Emory University
High-Risk Multiple Myeloma: New Definitions, Diagnostics, and Promising Therapies
Despite significant advancements in multiple myeloma (MM) treatment, a quarter of newly diagnosed patients survive less than three years, particularly those with high-risk MM. This aggressive subset, representing about 20%...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Accurate Diagnostic Model for Newly Diagnosed Multiple Myeloma
Researchers of a recent study aimed to identify clinical laboratory parameters for diagnosing newly diagnosed multiple myeloma (NDMM) and develop a diagnostic model for early and precise detection....
NSD2 Overexpression in t(4;14) Multiple Myeloma Identifies AK2 as a New Therapeutic Target
In a recently published study, researchers revealed that NSD2 overexpression in t(4;14) multiple myeloma (MM) redirects S-adenosylmethionine (SAM) toward excessive methylation of the epigenome, specifically histone H3K36 dimethylation....
Study Revises Prognostic Staging System for Multiple Myeloma, Enhancing Stratification With New Risk Factors
Patients with newly diagnosed multiple myeloma (NDMM) exhibit varying outcomes, with around 60% classified as intermediate-risk under the Revised International Staging System (R-ISS). Chromosome 1q gain/amplification (1q+) has recently been...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
mSMART Guidelines Influence Global Multiple Myeloma Care with Updated, Risk-Based Protocols
The Stratification for Myeloma and Risk-Adapted Therapy (mSMART) guidelines, developed to provide clear and effective treatment protocols for multiple myeloma, were introduced due to the lack of structured treatment approaches...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Increased Risks for Patients With Multiple Myeloma
Patients with monoclonal gammopathy of undetermined significance or smoldering multiple myeloma are at a higher risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukemia compared to the general population....
